Baclofen’s role in managing alcohol use disorder (AUD) has evolved significantly, especially in France, where it’s approved as a targeted therapy. Initially developed to relieve muscle spasticity, baclofen’s potential to reduce alcohol cravings was confirmed in early studies and clinical trials. Its success in helping AUD patients maintain abstinence drove widespread research into its mechanisms and therapeutic value. French physicians often customize baclofen prescriptions to match individual needs, with doses ranging from 30 to 300 mg/day based on patient tolerance and craving severity. This dosing flexibility offers benefits in helping patients maintain abstinence, but high doses increase the risk of severe adverse effects (SAEs) like sedation, confusion, and even hospitalization. Observational studies demonstrate that under careful monitoring, tailored dosing can significantly improve outcomes for AUD patients. However, comprehensive patient education and close physician oversight are vital to managing risks, especially with high doses.
de Beaurepaire, R. and Jaury, P., 2024.Baclofen in the treatment of alcohol use disorder: tailored doses matter. Alcohol and Alcoholism.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Baclofen 10 AMPULES by Swiss Remedies, consult with your doctor or healthcare professional.
de Beaurepaire, R. and Jaury, P., 2024.Baclofen in the treatment of alcohol use disorder: tailored doses matter. Alcohol and Alcoholism.
de Beaurepaire, R. and Jaury, P., 2024.Baclofen in the treatment of alcohol use disorder: tailored doses matter. Alcohol and Alcoholism.
de Beaurepaire, R. and Jaury, P., 2024.Baclofen in the treatment of alcohol use disorder: tailored doses matter. Alcohol and Alcoholism.